Annexon earnings release, August 12, 2026

Annexon, Inc. (ANNX) · Form 8-K, Item 2.02 · Filed · SEC filing

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect

Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026

Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary Endpoint Strategy and Launch of Open-Label Extension Study; Month 15 Primary Endpoint on Track for Q4 2026

POC Data for ANX1502, a

First-in-Kind

Oral C1 Inhibitor for

Autoimmune Disease, Expected in Fall 2026

$200 Million Credit Facility Strengthens Balance Sheet and Capabilities; Anticipated

Runway Extended into 2028

Company to Host Business Update Call Today at 8:00 a.m. ET

BRISBANE, Calif., August 12, 2026 – Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today highlighted portfolio progress, announced key anticipated milestones, and reported second quarter 2026 financial results. The Company will host a business update call today at 8:00 a.m. ET to discuss corporate and clinical developments across its

C1q-focused neuroinflammatory pipeline. Please register for the event here.

“2026 is a defining year for our company, with meaningful progress across both our Guillain-Barré syndrome (GBS) and geographic atrophy (GA) programs that position us to potentially deliver two transformative therapies for millions of patients in need. The quality and consistency of the data generated to date reinforce our confidence in the differentiated potential of our

C1q-targeted approaches to address neuroinflammatory diseases at their source, and we are encouraged by the growing enthusiasm from patients and physicians,” said Douglas Love, president and chief executive officer of Annexon. “With our leadership capabilities and financial position strengthened, we are entering an exciting period of execution, with multiple important clinical and regulatory milestones expected over the next 6 to 12 months and a significant opportunity to create value for patients and stakeholders.”

2026 Strategic Priorities and Key Milestones

Tanruprubart: Potential to be the first targeted, fast-acting therapy for GBS, an indiscriminate life-threatening neuromuscular emergency affecting 150,000 people annually worldwide and driving an estimated $20+ billion annual healthcare burden in the U.S.

Vonaprument: Potential to be the first targeted vision-preserving therapy for GA, a leading cause of blindness affecting more than 8 million patients worldwide.

ANX1502 for Autoimmune

Conditions:

First-in-kind oral small molecule inhibiting activated C1s, with convenient and flexible dosing.

Corporate Updates

Second Quarter 2026 Financial Results

Corporate Webcast Details

Annexon will host a webcast at

8:00 a.m. ET today, August 12, 2026. Please register for the webcast here. The live webcast and replay may be also accessed by visiting Annexon’s website at https://ir.annexonbio.com/events-and-presentations/events.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended June 30, — (in thousands, except share and per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating expenses:Research and development (1)46,59044,16082,37692,339
Operating expenses:General and administrative (1)10,6377,56620,90416,792
Operating expenses:Total operating expenses57,22751,726103,280109,131
Operating expenses:Loss from operations-57,227-51,726-103,280-109,131
Operating expenses:Interest and other income, net1,8792,5703,7905,619
Operating expenses:Net loss-55,348-49,156-99,490-103,512
Operating expenses:Deemed dividend on modification of common stock warrants-1,857-1,857
Operating expenses:Net loss attributable to common stockholders-55,348-51,013-99,490-105,369
Operating expenses:Net loss per share, basic and diluted-0.28-0.34-0.5-0.71
Operating expenses:Weighted-average shares used in computing net loss per share, basic and diluted201,003,269148,320,803197,620,477148,215,392

Balance Sheet

June 30, 2026 — (in thousands)

June 30, 2026 – (Unaudited)December 31, 2025
Current assets:Cash and cash equivalents199,270162,051
Current assets:Short-term investments9,97376,294
Current assets:Prepaid expenses and other current assets3,5143,846
Current assets:Total current assets212,757242,191
Current assets:Restricted cash1,0321,032
Current assets:Property and equipment, net9,67510,617
Current assets:Operating lease right-of-use assets14,33315,185
Current assets:Other non-current assets8,2718,546
Current assets:Total assets246,068277,571
Current liabilities:Accounts payable15,73114,931
Current liabilities:Accrued and other current liabilities19,62524,791
Current liabilities:Operating lease liabilities, current3,1262,908
Current liabilities:Total current liabilities38,48242,630
Current liabilities:Operating lease liabilities, non-current21,52523,293
Current liabilities:Total liabilities60,00765,923
Stockholders’ equity:Common stock175149
Stockholders’ equity:Additional paid-in capital1,202,8471,128,917
Stockholders’ equity:Accumulated other comprehensive loss-82-29
Stockholders’ equity:Accumulated deficit-1,016,879-917,389
Stockholders’ equity:Total stockholders’ equity186,061211,648
Stockholders’ equity:Total liabilities and stockholders’ equity246,068277,571
Full release

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”

“contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”

“plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the potential for the company’s two late stage registrational programs to improve the lives of millions of patients; timing of and topline data from the Month 15 primary endpoint and Month 24 primary endpoint in the pivotal Phase 3 ARCHER II trial; the potential of vonaprument to be the first targeted vision-preserving therapy for GA; the potential of tanruprubart to be the first targeted and fast-acting therapy for GBS; expectation of multiple important clinical and regulatory milestones over the next 6 to 12 months; timing of a BLA submission with supportive initial U.S./European data from FORWARD trial; timing of POC trial data for ANX1502 in

CAD; anticipated cash runway into 2028; and continuing advancement of the company’s portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and... (truncated)al results from the Phase 3 ARCHER II trial; the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the potential for delays in the company’s clinical trials, including if the FDA and comparable foreign regulatory authorities do not accept data from clinical trials for product candidates outside the United States; the early stages of clinical development of the company’s product candidates; the effects of public health crises on the company’s clinical programs and business operations; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s most recent Annual Report on Form

10-K and Quarterly Reports on Form

10-Q and the company’s other filings with the Securities and Exchange Commission. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Joyce Allaire

LifeSci Advisors jallaire@lifesciadvisors.com

Media Contact:

Beth Keshishian

917-912-7195 beth@bethkeshishian.com

ANNEXON, INC.

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share amounts)

ANNEXON, INC.

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Annexon earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.